Efficiency of recombinant thymosin β4 in spontaneous mouse model of chronic dermatitis.

Bulletin of experimental biology and medicine2015PMID: 25778656

View on PubMed DOI: 10.1007/s10517-015-2831-y

Animal StudyTB-500

Plain Language Summary

Tests recombinant thymosin β4 in the spontaneous CBRB mouse model of chronic dermatitis—an animal model analogous to human chronic inflammatory skin disease. Three TB4 applications per week significantly alleviated dermatitis symptoms; combined with antibacterial/antifungal therapy produced pronounced, lasting (2-month) therapeutic effect. Demonstrates TB4's efficacy in a spontaneous, non-induced chronic skin inflammation model—establishing TB4 as a combinatorial therapeutic partner with antimicrobials for chronic dermatological conditions.

Abstract

The therapeutic efficiency of recombinant thymosin β4 (rTβ4) synthesized by us was studied in vivo on spontaneous CBRB mouse model that is adequate to human chronic dermatitis. Three applications of the drug during a week significantly alleviated symptoms of the disease in female mice, and in complex with subsequent antibacterial and antifungal therapy led to a pronounced and lasting (2 months) therapeutic effect. The results attest to a possibility of using rTβ4 in combination with the known treatment protocols for chronic inflammatory diseases of the skin.

Authors

Moiseeva, E V; Beirakhova, K A; Semushina, S G; Aronov, D A; Makarov, D A; Esipov, R S